American Association for Cancer Research https://www.bioworld.com/rss en-us Calidi details characterization of CLD-401 for solid tumor treatment http://www.bioworld.com/articles/729156 Tue, 03 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729156-calidi-details-characterization-of-cld-401-for-solid-tumor-treatment 3D representation of tumor ARV-6723 shows robust efficacy in solid tumors http://www.bioworld.com/articles/729135 Mon, 02 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729135-arv-6723-shows-robust-efficacy-in-solid-tumors Cancer cell in the cross-hairs ANK-203: first CD137-anchored therapy with strong antitumor activity http://www.bioworld.com/articles/729014 Tue, 24 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729014-ank-203-first-cd137-anchored-therapy-with-strong-antitumor-activity First-in-class LTβR x EDB bispecific antibody overcomes checkpoint resistance http://www.bioworld.com/articles/728972 Mon, 23 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728972-first-in-class-ltr-x-edb-bispecific-antibody-overcomes-checkpoint-resistance Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow Ampersand reports AMP-410 data at AACR IO http://www.bioworld.com/articles/728954 Fri, 20 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728954-ampersand-reports-amp-410-data-at-aacr-io Antibodies attacking cancer cell Epimab sells bispecific T-cell engager to Juri in $210M deal http://www.bioworld.com/articles/720935 Wed, 04 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/720935-epimab-sells-bispecific-t-cell-engager-to-juri-in-210m-deal Handshake with globe background and digital overlay Epimab sells bispecific T-cell engager to Juri in $210M deal http://www.bioworld.com/articles/720915 Tue, 03 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720915-epimab-sells-bispecific-t-cell-engager-to-juri-in-210m-deal Handshake with globe background and digital overlay Epimab sells bispecific T-cell engager to Juri in $210M deal http://www.bioworld.com/articles/720505 Wed, 28 May 2025 11:00:00 -0400 https://www.bioworld.com/articles/720505-epimab-sells-bispecific-t-cell-engager-to-juri-in-210m-deal Handshake with globe background and digital overlay SY-9453 shows efficacy at treating tumors with MTAP deficiency MTAP and CDKN2A genes, which results in sensitization to MAT2A inhibitors, thus opening a therapeutic window in these cancer types. MAT2A inhibitors have demonstrated efficacy in MTAD-deficient cancers. Shouyao Holdings (Beijing) Co. Ltd. has developed and released data for their MAT2A inhibitor SY-9453 for the treatment of MTAP-deficient cancers.]]> http://www.bioworld.com/articles/720700 Tue, 27 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720700-sy-9453-shows-efficacy-at-treating-tumors-with-mtap-deficiency Sutro Biopharma unveils best-in-class anti-tissue factor ADC http://www.bioworld.com/articles/720542 Fri, 23 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720542-sutro-biopharma-unveils-best-in-class-anti-tissue-factor-adc 3D illustration demonstrating antibody-drug conjugate. SNV-5686 selectively degrades WRN in MSI-H cancer models WRN gene. Pharmacologic inhibition of WRN has been shown to selectively impair the viability of MSI-H cancer cells, effectively blocking tumor growth while sparing microsatellite-stable (MSS) cells.]]> http://www.bioworld.com/articles/720540 Fri, 23 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720540-snv-5686-selectively-degrades-wrn-in-msi-h-cancer-models Cancer cells under magnifying glass SY-9453 shows efficacy at treating tumors with MTAP deficiency MTAP and CDKN2A genes, which results in sensitization to MAT2A inhibitors, thus opening a therapeutic window in these cancer types. MAT2A inhibitors have demonstrated efficacy in MTAD-deficient cancers. Shouyao Holdings (Beijing) Co. Ltd. has developed and released data for their MAT2A inhibitor SY-9453 for the treatment of MTAP-deficient cancers.]]> http://www.bioworld.com/articles/720539 Fri, 23 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720539-sy-9453-shows-efficacy-at-treating-tumors-with-mtap-deficiency Novel peptide-drug conjugate achieves durable tumor retention with favorable safety profile http://www.bioworld.com/articles/720520 Thu, 22 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720520-novel-peptide-drug-conjugate-achieves-durable-tumor-retention-with-favorable-safety-profile Art concept for drug research MALT1 inhibitor SY-12696 proves efficient for treating BTKi-resistant DLBCL http://www.bioworld.com/articles/720370 Tue, 20 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720370-malt1-inhibitor-sy-12696-proves-efficient-for-treating-btki-resistant-dlbcl Photomicrograph of diffuse large B-cell lymphoma Data support benefit of MUC1*-targeted ADCs in trastuzumab-resistant patients http://www.bioworld.com/articles/720308 Mon, 19 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720308-data-support-benefit-of-muc1-targeted-adcs-in-trastuzumab-resistant-patients 3D rendering of an antibody-drug conjugate SY-13380: A novel menin/KMT2A inhibitor for aggressive leukemia http://www.bioworld.com/articles/720291 Fri, 16 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720291-sy-13380-a-novel-menin-kmt2a-inhibitor-for-aggressive-leukemia Preclinical studies support XNW-29016’s potential for treating HRD cancers http://www.bioworld.com/articles/720289 Fri, 16 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720289-preclinical-studies-support-xnw-29016s-potential-for-treating-hrd-cancers Microscope with laptop displaying histology image. DAT-5000A has potency against tumors with microsatellite instability http://www.bioworld.com/articles/720286 Fri, 16 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720286-dat-5000a-has-potency-against-tumors-with-microsatellite-instability New anti-CCR8 immuno-oncology antibodies with unique binding/pharmacology http://www.bioworld.com/articles/720215 Thu, 15 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720215-new-anti-ccr8-immuno-oncology-antibodies-with-unique-binding-pharmacology Antibodies attacking cancer cell QX-001280 exerts synergistic antitumoral activity when combined with olaparib http://www.bioworld.com/articles/720211 Thu, 15 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720211-qx-001280-exerts-synergistic-antitumoral-activity-when-combined-with-olaparib Integrating antibody therapy and oncolytic virotherapy enhances effects http://www.bioworld.com/articles/720163 Wed, 14 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720163-integrating-antibody-therapy-and-oncolytic-virotherapy-enhances-effects 3D illustration of cancer in crosshairs GPR171 is a prognostic marker in cervical cancer http://www.bioworld.com/articles/720162 Wed, 14 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720162-gpr171-is-a-prognostic-marker-in-cervical-cancer Chinese researchers unveil new agent for KRAS G12D-mutated tumors http://www.bioworld.com/articles/720198 Tue, 13 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720198-chinese-researchers-unveil-new-agent-for-kras-g12d-mutated-tumors New 5T4-targeted radiopharmaceutical shows single-dose efficacy in preclinical cancer models http://www.bioworld.com/articles/720139 Tue, 13 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720139-new-5t4-targeted-radiopharmaceutical-shows-single-dose-efficacy-in-preclinical-cancer-models BB-1705 optimizes profile of EGFR-targeting therapies http://www.bioworld.com/articles/720137 Tue, 13 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720137-bb-1705-optimizes-profile-of-egfr-targeting-therapies Integrating AI-based neoantigen prediction and APC-targeted delivery to enhance cancer immunotherapy http://www.bioworld.com/articles/720080 Mon, 12 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720080-integrating-ai-based-neoantigen-prediction-and-apc-targeted-delivery-to-enhance-cancer-immunotherapy Digital cancer cells illustration KGX-103 exerts antitumoral activity in vivo in A375 melanoma model http://www.bioworld.com/articles/720079 Mon, 12 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720079-kgx-103-exerts-antitumoral-activity-in-vivo-in-a375-melanoma-model Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1. HW-321005, a novel KAT6A/6B inhibitor with strong antiproliferative activity http://www.bioworld.com/articles/720077 Mon, 12 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720077-hw-321005-a-novel-kat6a-6b-inhibitor-with-strong-antiproliferative-activity SYS-6041 shows promise for treating FOLR1-expressing cancers http://www.bioworld.com/articles/720063 Fri, 09 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720063-sys-6041-shows-promise-for-treating-folr1-expressing-cancers mRNA-based cancer vaccine targeting mutated EGFR shows antitumor efficacy http://www.bioworld.com/articles/720062 Fri, 09 May 2025 09:00:00 -0400 https://www.bioworld.com/articles/720062-mrna-based-cancer-vaccine-targeting-mutated-egfr-shows-antitumor-efficacy 3D illustration and light micrograph of lung cancer.